RVL PHARMS
PharmaRVL PHARMS is a pharmaceutical company with 1 FDA-approved products.
RVL PHARMS at a Glance
- Fast trial execution (14 months median completion)
RVL PHARMS's Key Drugs
RVL PHARMS's core commercial portfolio centers on UPNEEQ — its most strategically important drugs approved in the last 15 years.
RVL PHARMS's Recent FDA Approvals
New NDA/BLA approvals for RVL PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
RVL PHARMS's Therapeutic Areas
Disease areas where RVL PHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
RVL PHARMS Pipeline Snapshot
Active clinical trials for RVL PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • UPNEEQ leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 7/9 completed
- • Speed: 14 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2020-07-08
- Latest
- 2021-05-05
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges